Status:
COMPLETED
Topiramate Augmentation in the Treatment of Obsessive-Compulsive Disorder
Lead Sponsor:
Montefiore Medical Center
Collaborating Sponsors:
Ortho-McNeil Pharmaceutical
Conditions:
Obsessive-compulsive Disorder
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
A 12-week program to examine the effectiveness of topiramate in adjunctive treatment for adults with obsessive-compulsive disorder and who are currently on serotonin reuptake inhibitor medications (ag...
Detailed Description
The Compulsive, Impulsive and Anxiety Disorders Program at the Mount Sinai School of Medicine is conducting a study of Topiramate (Topamax) added to an SSRI for the management of treatment-resistant O...
Eligibility Criteria
Inclusion
- Males and Females 18-65 years of age diagnosed with OCD and currently taking SSRI medication(s)
Exclusion
- major medical disorders
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00211744
Start Date
August 1 2004
End Date
August 1 2006
Last Update
May 30 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mount Sinai School of Medicine
New York, New York, United States, 10029